Management of Dysfunctional Hemodialysis Catheter After Maximal Heparin Failure

Immediate Pharmacologic Intervention

Alteplase (tPA) 1–2 mg per lumen is the FDA‑approved thrombolytic for hemodialysis catheter dysfunction and should be administered when maximal heparin dosing fails. 1
Allow a dwell time of 30 minutes to 2 hours before attempting aspiration to maximize thrombolytic contact with the intraluminal clot. 2
One dose of tPA restores flow in ~72 % of catheters; a second dose raises success to ~83 %. 3
If the initial dwell is ineffective, an intradialytic tPA infusion (≈2.5 mg per lumen over 1–2 hours) can be given during the dialysis session. 6
Urokinase is an alternative thrombolytic when available, although convenient formulations are no longer produced. 1
Intradialytic urokinase (≈20,000 U per lumen per hour for 6 hours) may restore flow when simple dwell techniques fail. 6

Perform a contrast catheter study to differentiate the cause of dysfunction (intraluminal thrombus, fibrin sheath, malposition, or vessel stenosis); fibrin sheaths are present in up to 76 % of catheters. 1
Fibrin sheaths can develop as early as 24 hours after insertion and may encase the entire catheter within 5–7 days. 2
Preferred technique: exchange the catheter over a guidewire, disrupt the fibrin sheath with an angioplasty balloon, and place a new catheter. This approach yields cumulative patency of 31–93 % at 1 month and 45–56 % at 3 months. 2
Alternative mechanical options with comparable efficacy: percutaneous fibrin‑sheath stripping, angioplasty balloon disruption alone, or internal snare maneuver. 8

Replace standard heparin lock with recombinant tPA (1 mg per lumen weekly) as a locking solution; this significantly lowers catheter dysfunction and infection rates. 2
Gentamicin‑citrate lock solutions reduce catheter‑related bloodstream infections by ~73 % (0.45 vs 1.68 infections per 1,000 catheter‑days) and have demonstrated mortality reduction. 2
4 % sodium citrate combined with antimicrobial additives (e.g., gentamicin, taurolidine, methylene blue) provides superior outcomes compared with heparin alone. 2

Low‑dose warfarin (1–2 mg daily) may decrease thrombosis in high‑risk dialysis patients, but bleeding risk must be weighed. 10
Current evidence is insufficient to support routine use of low‑molecular‑weight heparin or therapeutic‑dose warfarin for primary prevention of catheter thrombosis. 2

Do not continue escalating heparin beyond the maximal dose; this raises bleeding risk without improving catheter flow. 1
Do not delay thrombolytic therapy while awaiting extensive diagnostics; early tPA administration improves success rates. 1
Do not perform a simple catheter exchange without disrupting an existing fibrin sheath, as this leads to early recurrent dysfunction. 6
Do not replace the catheter before attempting thrombolytic therapy; thrombolysis is less invasive and more cost‑effective. 1